Without a doubt, the brightest star in the summer night sky is Arcturus. It’s the second-brightest star in our night skies throughout the year. Only Sirius, the brightest star in the constellation ...
Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA vaccine trial, despite reports swirling that Moderna’s own financial support ...
San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...
Arcturus Therapeutics is transitioning from COVID-era revenues to milestone-driven growth, led by its mRNA platform and strategic partnerships. KOSTAIVE, ARCT's self-amplifying mRNA COVID-19 vaccine, ...
Hosted on MSN
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating
We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while ...
Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results